DongKook Pharmaceutical Co., Ltd. (KOSDAQ:086450)
South Korea · Delayed Price · Currency is KRW 18,760
+860 (4.80%)
At close: Mar 20, 2026
DongKook Pharmaceutical Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 926,884 | 812,166 | 730,994 | 661,647 | 594,193 |
Other Revenue | - | - | - | -0 | - |
| 926,884 | 812,166 | 730,994 | 661,647 | 594,193 | |
Revenue Growth (YoY) | 14.12% | 11.10% | 10.48% | 11.35% | 6.28% |
Cost of Revenue | 425,655 | 364,598 | 320,443 | 281,999 | 244,272 |
Gross Profit | 501,228 | 447,568 | 410,551 | 379,648 | 349,921 |
Selling, General & Admin | 359,001 | 328,148 | 310,542 | 277,684 | 257,570 |
Research & Development | 32,820 | 30,325 | 25,456 | 21,818 | 24,691 |
Amortization of Goodwill & Intangibles | 1,535 | 771.45 | 124.19 | 92.39 | 114.47 |
Other Operating Expenses | 1,607 | 1,343 | 1,278 | 1,350 | 887.7 |
Operating Expenses | 404,754 | 367,703 | 343,677 | 306,107 | 286,702 |
Operating Income | 96,474 | 79,865 | 66,873 | 73,541 | 63,219 |
Interest Expense | -2,077 | -4,497 | -5,868 | -4,320 | -2,883 |
Interest & Investment Income | 5,575 | 6,335 | 5,258 | 2,903 | 2,454 |
Earnings From Equity Investments | -3,689 | 2,553 | -896.71 | 1,122 | 1,031 |
Currency Exchange Gain (Loss) | -1,071 | 1,840 | -65.38 | 708.54 | 2,657 |
Other Non Operating Income (Expenses) | -1,633 | -6,790 | 596.82 | -603.97 | 932.71 |
EBT Excluding Unusual Items | 93,579 | 79,305 | 65,898 | 73,350 | 67,411 |
Gain (Loss) on Sale of Investments | -4,723 | 3,284 | -5,814 | -5,337 | 1,376 |
Gain (Loss) on Sale of Assets | 5,580 | 2,148 | 752.89 | 618.82 | 966.3 |
Asset Writedown | -1,848 | - | - | - | - |
Pretax Income | 92,588 | 84,738 | 60,838 | 68,632 | 69,754 |
Income Tax Expense | 18,655 | 22,401 | 11,966 | 13,876 | 16,837 |
Earnings From Continuing Operations | 73,933 | 62,336 | 48,871 | 54,757 | 52,916 |
Minority Interest in Earnings | -7,912 | -1,117 | -1,696 | -1,861 | -2,571 |
Net Income | 66,020 | 61,219 | 47,175 | 52,896 | 50,345 |
Preferred Dividends & Other Adjustments | - | - | 399.85 | - | - |
Net Income to Common | 66,020 | 61,219 | 46,775 | 52,896 | 50,345 |
Net Income Growth | 7.84% | 29.77% | -10.81% | 5.07% | -9.98% |
Shares Outstanding (Basic) | 44 | 44 | 44 | 44 | 44 |
Shares Outstanding (Diluted) | 45 | 45 | 45 | 45 | 45 |
Shares Change (YoY) | 0.02% | 0.04% | 0.02% | 0.01% | - |
EPS (Basic) | 1487.00 | 1382.00 | 1064.03 | 1203.46 | 1145.56 |
EPS (Diluted) | 1475.00 | 1368.00 | 1054.64 | 1183.00 | 1126.00 |
EPS Growth | 7.82% | 29.71% | -10.85% | 5.06% | -9.99% |
Free Cash Flow | 26,046 | 48,800 | 7,616 | -7,005 | -6,352 |
Free Cash Flow Per Share | 581.90 | 1090.48 | 170.27 | -156.64 | -142.04 |
Gross Margin | 54.08% | 55.11% | 56.16% | 57.38% | 58.89% |
Operating Margin | 10.41% | 9.83% | 9.15% | 11.12% | 10.64% |
Profit Margin | 7.12% | 7.54% | 6.40% | 7.99% | 8.47% |
Free Cash Flow Margin | 2.81% | 6.01% | 1.04% | -1.06% | -1.07% |
EBITDA | 128,186 | 108,327 | 87,971 | 92,728 | 80,577 |
EBITDA Margin | 13.83% | 13.34% | 12.03% | 14.02% | 13.56% |
D&A For EBITDA | 31,712 | 28,462 | 21,098 | 19,187 | 17,358 |
EBIT | 96,474 | 79,865 | 66,873 | 73,541 | 63,219 |
EBIT Margin | 10.41% | 9.83% | 9.15% | 11.12% | 10.64% |
Effective Tax Rate | 20.15% | 26.44% | 19.67% | 20.22% | 24.14% |
Advertising Expenses | 91,121 | 83,743 | 76,804 | 66,472 | 67,064 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.